interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Ceritinib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Ceritinib, and who makes it?

Ceritinib appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Ceritinib2 dosage-form groups in the Orange Book
0generic makers listed
  1. Ceritinib appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

2010201520202025203001brand 2014data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Zykadia. No generic is listed as marketed.

20152020202520302035204001brand 2019data datePatent 8377921 listed to expire 20 November 2027Patent 8399450 listed to expire 20 November 2027Patent 7964592 listed to expire 29 April 2028Patent 8039479 listed to expire 29 June 2030Patent 9309229 listed to expire 18 January 2032Patent 8703787 listed to expire 2 February 2032Patent 12357630 listed to expire 13 December 2037
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 20 November 2027Patent 8377921
  • 20 November 2027Patent 8399450 drug substance
  • 29 April 2028Patent 7964592 drug substance
  • 29 June 2030Patent 8039479 drug substance
  • 18 January 2032Patent 9309229 drug substance
  • 2 February 2032Patent 8703787
  • 13 December 2037Patent 12357630

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.